Literature DB >> 1469240

Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema.

B S Russman1, S T Iannacone, C R Buncher, F J Samaha, M White, B Perkins, L Zimmerman, C Smith, K Burhans, L Barker.   

Abstract

We have established the first prospective, collaborative study of spinal muscular atrophy, the second most common neuromuscular disease of childhood. One hundred and forty-one patients have been evaluated on at least four occasions over a 3-year period. The patients have been grouped by age of onset, as well as by function at the time of initial evaluation. The muscle strength of 96 patients aged 5 years or older was evaluated at 6-month intervals using a fixed myometry system. The new observations made are: (1) The present classification schema is not valid; for example, 49 patients with onset of weakness before 6 months of age (type I or Werdnig-Hoffmann disease), whose life span is said to be only 2 to 4 years, participated in the study and are 4 months to 31 years of age. (2) Thirty-seven patients were evaluated over an 18-month period. None lost strength during this time but four lost function. Although the period of observation was short, the results suggest that the loss of function in patients with spinal muscular atrophy might be explained by a process other than cell death that allows patient strength to be maintained and simultaneously prevents the motor unit from achieving its normal adult potential.

Entities:  

Mesh:

Year:  1992        PMID: 1469240     DOI: 10.1177/088307389200700403

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  6 in total

1.  Spinal muscular atrophy--type I.

Authors:  M K M Hardart; R D Truog
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

2.  Drug treatment for spinal muscular atrophy types II and III.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2020-01-06

Review 3.  Spinal muscular atrophy.

Authors:  Susan T Iannaccone; Stephen A Smith; Louise R Simard
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

4.  Prospective study of gross motor development in children with SMA type II.

Authors:  R Bono; M Inverno; G Botteon; E Iotti; M Estienne; A Berardinelli; G Lanzi; E Fedrizzi
Journal:  Ital J Neurol Sci       Date:  1995-05

5.  Vibration-Assisted Home Training Program for Children With Spinal Muscular Atrophy.

Authors:  Christina Stark; Ibrahim Duran; Sebahattin Cirak; Stefanie Hamacher; Heike-Katharina Hoyer-Kuhn; Oliver Semler; Eckhard Schoenau
Journal:  Child Neurol Open       Date:  2018-06-10

6.  Drug treatment for spinal muscular atrophy type I.

Authors:  Renske I Wadman; W Ludo van der Pol; Wendy Mj Bosboom; Fay-Lynn Asselman; Leonard H van den Berg; Susan T Iannaccone; Alexander Fje Vrancken
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.